

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue: **MedPlus Health Services Limited**

- | | |
|---|---|
| 1. Type of Issue (IPO/FPO) | IPO |
| 2. Issue Size (Rs. Cr) | INR 1,398.295 Cr |
| 3. Grade of issue along with name of the rating agency | |
| Name | NA |
| Grade | NA |
| 4. Subscription Level (Number of times) | The Offer was subscribed 52.8582 times (excluding the Anchor Investor Portion and after removing multiple and duplicate bids and technical rejection cases) * |

*Source-Minutes of Basis of Allotment dated December 20, 2021

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	7.33%*
(ii) at the end of the 1st Quarter immediately after the listing of the issue^^	31.14%
(iii) at the end of 1st FY (March 31, 2022)**	32.21%
(iv) at the end of 2nd FY (March 31, 2023)**	32.65%
(v) at the end of 3rd FY (March 31, 2024)***	37.41%

(*) As a % of total post issue paid up capital as per Prospectus dated December 16, 2021

^^ Shareholding Pattern filed with Stock Exchange for the quarter ended December 31, 2021

** Shareholding Pattern filed with Stock Exchange for the quarter ended March 31, 2022 & March 31, 2023

*** Shareholding Pattern filed with Stock Exchange for the quarter ended March 31, 2024

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated (Rs in Crores)

Parameters	1st FY (March 31, 2022)**	2nd FY (March 31, 2023)**	3rd FY (March 31, 2024)**
Income from operations	3779.27	4557.75	5624.86
Net Profit for the period	94.71	50.10	65.58
Paid-up equity share capital	23.86	23.86	23.91
Reserves excluding revaluation reserves	1393.91	1467.31	1554.03

Standalone (Rs in Crores)

Parameters	1st FY (March 31, 2022)**	2nd FY (March 31, 2023)**	3rd FY (March 31, 2024)**
Income from operations	145.71	213.92	467.03
Net Profit for the period	5.57	5.54	9.58
Paid-up equity share capital	23.86	23.86	23.91
Reserves excluding revaluation reserves	1088.92	1117.41	1148.72

** Source: Audited Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022, March 31, 2023 & March 31, 2024

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2024)	Frequently Traded

Source: Stock Exchange

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	None	None
(ii) at the end of 2nd FY (March 31, 2023)*	None	None
(iii) at the end of 3rd FY (March 31, 2024)	Mr. Atul Gupta	Non Executive Non Independent Director of the Company has tendered his resignation vide its letter dated September 26, 2023 with immediate effect. due to withdrawal of nomination rights from the Medplus Board by PI Opportunities Fund-1 ('Investor') consequence to reduction in the equity shares held which is less than 10% as per the shareholders Agreement
	Dr. Bhaskar Reddy Cherukupally	Appointment as an Additional Director (Executive) designated as Whole Time Director of the Company for a period of five years, with effect from October 26, 2023

The changes have been updated until May 30, 2024

9. Status of implementation of project/ commencement of commercial production

- (i) **As disclosed in the offer document: NA**
- (ii) **Actual implementation: NA**
- (iii) **Reasons for delay in implementation, if any: NA**

10. Status of utilization of issue proceeds

(i) As disclosed in the offer document:

(Rs. In Million)

Particulars	Amount to be funded from the Net Proceeds	Estimated deployment		
		Fiscal 2022	Fiscal 2023	Fiscal 2024
Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival	4,671.70	1,239.19	1,586.87	1,845.64
General corporate purposes	1,055.71	500	555.71	-
Total	5,727.41	1,739.19	2,142.58	1,845.64

(ii) Actual utilization:

(Rs. In Million)

Item Head	Amount as proposed in Offer Document	Amount utilized			Total unutilized amount as on March 31, 2024
		As at the beginning of the quarter March 31, 2024	During the Quarter March 31, 2024	At the end of quarter March 31, 2024	
Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival	4,671.70	4671.70	Nil	4671.70	NIL
General Corporate Purpose	1111.03	428.72	19.80	448.53	662.50
Total	5782.73	5,100.42	19.80	5,120.23	662.50 *

Source: Monitoring Agency report dated May 15, 2024 for the Quarter ended March 31, 2024.

* unutilized amount has been deployed into Fixed Deposit with HDFC Bank Limited and Axis Bank Limited.

(iii) Reasons for deviation, if any: None

Source: Monitoring Agency report dated, May 15, 2024 for the Quarter ended March 31, 2024.

11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	None
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	NA
(c) Any other reservations expressed by the monitoring agency about the end use of funds	None

Source: Monitoring Agency report dated, May 15, 2024 for the Quarter ended March 31, 2024.

12. Pricing Data

Issue Price (Rs.):	796/-
Designated Stock Exchange:	BSE
Listing Date:	December 23, 2021

Price parameters	At close of listing day (i.e. December 23, 2021)	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue (March 31, 2022)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	1,120.85	1219.65	979.55	1010.25	1343	921
BSE SENSEX	57,315.28	59037.18	57989.3	58568.51	62245.43	47204.5
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2023)			As at the end of 3rd FY after the listing of the issue (March 31, 2024)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	651.15	1047.00	570.00	699.79	977.45	597.95
BSE SENSEX	58991.52	63583.07	50921.22	73651.35	74245.17	58793.08
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: BSE website

13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio		As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2022) ⁽⁴⁾	At the end of 2nd FY (March 31, 2023) ⁽⁴⁾	At the end of 3rd FY (March 31, 2024) ⁽⁴⁾
EPS	Issuer:	--	--	--	--
	Consolidated (Basic)	5.99	8.55	4.17	5.48
	Consolidated (Diluted)	5.75	8.52	4.17	5.45
	Peer Group ⁽³⁾ :	NA	NA	NA	NA
	Industry Avg:	NA	N.A	N.A	N.A
P/E	Issuer:	--	--	--	--
	Consolidated (Basic)	132.89	118.16	156.15	127.70
	Consolidated (Diluted)	138.43	118.57	156.15	128.40
	Peer Group ⁽³⁾ :	NA	NA	NA	NA
	Industry Composite:	NA	N.A	N.A	N.A
RoNW (%)	Issuer:	--	--	--	--
	Consolidated	8.74	0.50	3.36	4.16
	Peer Group ⁽³⁾ :	NA	NA	NA	NA
	Industry Composite:	NA	N.A	N.A	N.A
NAV	Issuer:	--	--	--	--
	Consolidated	65.37	93.28	124.99	131.99
	Peer Group ⁽³⁾ :	NA	NA	NA	NA

	Industry Avg:	NA	N.A	N.A	N.A
--	---------------	----	-----	-----	-----

Notes:

- (1) Prospectus dated December 16, 2021
- (2) Not disclosed as the reporting for the relevant fiscal years has not been completed.
- (3) There are no listed companies in India that engage in a business similar to that of the Company. Accordingly, it is not possible to provide an industry comparison in relation to the Company
- (4) Source: Audited Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022 March 31, 2023 & March 31, 2024.

14. Any other material information

Particulars	Date
The Company has informed the Exchange that Mr. Parag Jain, Company Secretary and Compliance Officer has resigned w.e.f January 14, 2022. He has also ceased to be the Company Secretary of the Company's Subsidiary and Material Subsidiary.	January 13, 2022
The Company has informed the Exchange that Ms. Shilpi Keswani is appointed as the Company Secretary and Compliance Officer w.e.f January 15, 2022	January 13, 2022
The Company has informed the Exchange that the new Registered Office of the Company is H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad - 500037, Telangana, India with effect from 2nd May, 2022	May 3, 2022
The Company has informed the Exchange that Mr. Hemanth Kundavaram has resigned from the post of Chief Financial Officer ('CFO') and Key Managerial Personnel of the MedPlus Health Services Limited ('Company'), Optival Health Solutions Private Limited and Wynclark Pharmaceuticals Private Limited, subsidiaries of the Company. Mr. Kundavaram will continue to act as the CFO of the Company until Sunday, 5th June, 2022.	June 4, 2022
The Company has informed the Exchange that the Company has incorporated a wholly-owned subsidiary namely, 'MedPlus Insurance Brokers Private Limited'. As per the Certificate of Incorporation dated 14th July 2022 issued by the Registrar of Companies, Ministry of Corporate Affairs, the date of incorporation of wholly-owned subsidiary is 14th July, 2022.	July 15, 2022
The Company has informed the Exchange that Mr. Sujit Kumar Mahato, as Chief Financial Officer of the Company with effect from 11th November, 2022	November 11, 2022
The Company has informed the Exchange about the approval of the Scheme of Amalgamation ("Scheme") under Section 230 to Section 232 and other relevant provisions of the Companies Act, 2013 for amalgamation between MedPlus Health Services Limited ("Transferee Company") and MHS Pharmaceuticals Private Limited ("Transferor Company"), subject to requisite approvals	January 11, 2023
The Company has informed the exchange about the appointment of Mr. Manoj Kumar Srivastava as the Head Company Secretary and Compliance officer of the Company as required under Section 203 of the Companies Act, 2013, Regulation 6 of the SEBI (Listing Regulations and Disclosure Requirements), 2015, and Regulation 9(3) of the SEBI (Prohibition of Insider Trading) Regulations 2015, with effect from 30th March 2023 in place of Ms. Shilpi Keswani who has demitted the office of Company Secretary and Compliance officer of the company from the close of business hours of 30th March 2023.	March 30, 2023
The Company has inter alia informed following : 1) Appointment of M/s. Ernst & Young LLP as Internal Auditor of the Company. 2) The Company has made a strategic decision and launched various products in the Retail trading of medicines and general items segment under its own brand name. These are provided through a membership	August 07, 2023

model at a discount. The company will continue to explore opportunities to increase its product base under its own brand name. This could have an impact on the business, financial condition and results or operations.	
The Company has informed about the approval of Scheme of Amalgamation ("Scheme") under Section 230 to 232 and other relevant provisions of the Companies Act, 2013 for amalgamation between MedPlus Health Services Limited and MHS Pharmaceuticals Private Limited, the wholly owned subsidiary company	August 08, 2023
Pursuant to the Disclosure under Regulation 30(2) read with Clause 5A of Para A of Part A of Schedule III, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") read with SEBI Circular bearing No. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 dated 13.07.2023 ("SEBI Circular") the agreements forming a part of this disclosure have been initiated before the listing of equity shares of the Company and were part of our Draft Red Herring Prospectus (DRHP) filed on August 16, 2021 and Prospectus filed on December 16, 2021. The Company was listed on December 23, 2021. All such agreements as required in the said provision have already been provided in the DRHP and Prospectus as mentioned above. However, as an abundant caution the details were resubmitted by the Company.	August 14, 2023
The Company has informed about ongoing litigation Pursuant to the amendment to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 July 13, 2023.	August 28, 2023
The Company has informed about the conducting a survey by the Income Tax Department ("IT Department") on its subsidiary company.	September 14, 2023
The Company has informed about approval by its board for appointment and fixation of the remuneration of M/s MPR & Associates, Cost Accountant as Cost Auditor of the Company for the financial year 2023-24, subject to the ratification of remuneration by the shareholders.	September 21, 2023
The Company has informed about the Alteration in Articles of Association of the Company by Insertion of Article 102 A for Nomination Rights of Promoters.	September 29, 2023
The Company has informed about the consideration and evaluation and approval of its board to raise funds by way of, including issue of equity shares or any other equity linked instruments or securities, including convertible preference shares/ fully or partly convertible debentures or by way of a composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares, or any other eligible securities through inter alia, a private placement /QIP (including one or more qualified institutions placements) / further public issue of equity/ debt securities, preferential issue or a rights issue or through any other permissible mode under applicable laws and/ or combination thereof, as may be considered appropriate, for cash and at such premium/ discount, as applicable, subject to such approvals as may be required, including the approval of the Members at a General Meeting or through Postal Ballot and further subject to such other statutory/regulatory/other approvals, as applicable.	October 5, 2023
The Company has informed about the approval by its Board for raising of funds upto Rs 1200 Cr. (Twelve hundred crore rupees) by way of issue of equity shares or any other equity linked instruments or securities, including convertible preference shares/ fully or partly convertible debentures or by way of a composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares, or any other eligible securities or a combination of any of the Securities("Securities") mentioned above in one or more tranches through one or more public and/ or private offerings including by way of one or more qualified institutions placements/further public issue of equity/ debt securities, or a rights issue or through any other permissible mode under applicable laws and/ or combination thereof, as may be considered appropriate, for cash and at such premium/ discount, as applicable, subject to such approvals as may be required, including the approval of the Members at a General Meeting or through Postal Ballot and further subject to such other statutory/regulatory/other approvals, as applicable	October 11, 2023
The Company has informed about the receipt of order dated October 19,	October 21, 2023

2023 to its subsidiary company from the Sales Licencing & Enforcement Authority, Medchal, Malkajgiri District, Telangana for suspension of drug license for one of pharmacy outlet.	
The Company has informed about the Notice of separate meetings of the Equity Shareholders and the Unsecured Creditors of the Company as directed by the National Company Law Tribunal, Hyderabad Bench - 1 ('NCLT') vide its Order dated November 7, 2023 in the matter of Scheme of Amalgamation of MHS Pharmaceuticals Private Limited ("Transferor Company") with MedPlus Health Services Limited ("Transferee Company" or "Company") and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("the Act") and the rules framed thereunder ("Scheme of Amalgamation")	November 10, 2023
The Company has informed about the receipt of orders from Drugs and Control Authority to its subsidiary company for Suspension of drug license due to Violation of various conditions of licences pursuant to provisions of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	November 29, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of drug license for 1 days & 5 days respectively by the Assistant Director, Drugs Control Administration, Rangareddy Government of Telangana Drugs Control Administration, Hyd, T.S & Assistant Director Drugs Control Administration, Warangal, Government of Telangana Drugs Control Administration, T.S respectively for Violation of various conditions of licences pursuant to provisions of Section / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 7, 2023.
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of drug license for 7 days & 3 days respectively by the Assistant Director, & Drugs Sales Licensing Authority Drug Control Administration, Tirupathi District and Chitoor District, Government of Andhra Pradesh & Assistant Director, Drugs Control Administration, Rangareddy Government of Telangana Drugs Control Administration, Hyd, T.S respectively for Violation of various conditions of licences pursuant to provisions of Section / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 8, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of drug license for 1 days, 2 days & 3 days respectively by the Assistant Director & Drug Sales licencing authority, Drug Control administration, Medchal District, Government of Telangana, Assistant Director & Drug Sales licencing authority, Drug Control administration, Ballari District, Government of Karnataka & Assistant Director & Drug Sales licencing authority, Drug Control administration, Bangalore Circle-5, Karnataka respectively for violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 13, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for Suspension of drug license for 2 days (Dec 21, 2023 to Dec 22, 2023 by the Assistant Director, Drugs Control Administration, Bellary Distrcit , Karnataka for Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 14, 2023
The Company has informed about the approval given by its shareholder for the Scheme of Amalgamation of MHS Pharmaceuticals Private Limited ("Transferor Company") with MedPlus Health Services Limited ("Transferee Company/Company") and their respective shareholders and creditors	December 15, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of drug license for 3 days, 7 days & 2 days by the Assistant Director, Drugs Control Administration, Bangalore Circle-5, Karnataka, Assistant Director& Drug sales licensing authority, Drug control administration, Bapatla District & Assistant Director, Drugs Control Administration, CHIKKAMAGALUR District , Karnataka for Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	December 16, 2023

The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of drug licence for 7 days by the Assistant Director & Drug Sales licencing authority, Drug Control administration, Bapatla District, Government of Andhra Pradesh for Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 19, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for Suspension of drug license for 5 days by the Assistant Director & Drug Sales licencing authority, Drug Control administration, Rangareddy District, Government of Telangana for Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 21, 2023
The Company has informed about the execution of pledge agreement by its promoters (Agilemed Investments Pvt. Ltd) with Catalyst Trusteeship Limited.	December 22, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for Suspension of drug license for 2 days by the Assistant Director & Drug Sales licencing authority, Drug Control administration, Belgaum District, Government of Karnataka for Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The Company further informed that the said order resulted into Estimated Sales Loss due to closure of store is Rs. 1,17,000 (approx..).	December 22, 2023
The Company has informed about the resignation of Dr. Surendranath Mantena, Chief Operating Officer – MedPlus Mart, a Senior Management Personnel of the Company has resigned from the services of the Company vide its letter dated 25.12.2023 with immediate effect.	December 25, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of drug licence for 3 days for store located at Erukenchery High Road, Chennai District, Tamil Nadu for Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 25, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for Suspension of drug license for 7 days, 3 days & 3 days respectively for the stores situated at Kongareddy Palli, Chittoor, District, Andhra Pradesh, at Horamavu Main Road, Bangalore & d at HBR Layout - 2, Bangalore for Violation of various conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	December 28, 2023
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for Suspension of drug license for 3 days, 3 days, 2 days, 3 days & 2 days respectively for store located at Kengeri N S Town, at Horamavu Agara Village, at Hoysala Nagar Tc Palya Main Road, at Aiyappa Nagar & at Kengeri Robin Theatre respectively for Violation of various conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 02, 2024
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of Suspension of drug license for 6 days & 7 days respectively for store located at Shankarayapally Jadcherla & at Hayath Nagar respectively for Violation of various conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 05, 2024
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of Suspension of drug license for 5 days & 3 days respectively for sales premises at Padmavathi colony Hasthinapuram & at Mangalapally Village Bongloor for Violation of various conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 06, 2024
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of Suspension of drug license for 2 days & 4 days respectively for sale permission premises at Subhash road sadashivpet & at Medplus Pathan Nagar Ambajogai Road for Violation of various	January 09, 2024

conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of Suspension of drug license for 3 days for sale permission premises at Brothern Church Rajamahendravaram for Violation of various conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	January 11, 2024
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of Suspension of drug license for 7 days for sale permission premises at MedPus Tadepalli for Violation of various conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	January 12, 2024
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of Suspension of drug license for 7 days for sale permission premises at Jadcherla for Violation of various conditions of licences issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	January 15, 2024
The Company has informed about the receipt of order of Drugs and Control Authority to its Subsidiary Company for suspension of drug license (1-2 days) for its stores situated at various location in Bangalore Circle due to violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 17, 2024
The Company has informed about the receipt of order from the Drugs and Control Authority of Andhra Pradesh & Bangalore to its Subsidiary Company for suspension of drug license for 7 & 1 days respectively due to Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 18, 2024
The Company has informed about the receipt of order from the of Drugs and Control Authority to its Subsidiary Company for Suspension of Drug License for the store situated at: I. Muslim Chowk II. Aland Road Gulbarga for 1 day each store & Kurmannapalem for 7 days due to Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 22, 2024
The Company has informed about the receipt of order from the Drugs and Control Authority to its Subsidiary Company for Suspension of Drug License for two days of the store situated at Kumara Park Serpetine Road due to Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 24, 2024
The Company has informed about the receipt of order from the Drugs and Control Authority to its Subsidiary Company for Suspension of Drug License for the store situated at KG Nagar-Chamrajpet for 1 day & Thapovanam Colony Kharmangot Road for 5 days & Nanded City for 7 days due to Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	January 29, 2024
The Company has informed about the receipt of demand order of Rs. Rs. 1,88,96,802/- (Rs. One Crore eighty-eight lakhs ninety-six thousand eight hundred two) to its subsidiary company from the Regional Provident Fund Commissioner- I, Pune-I for incorrect claim made under Atmanirbhar Bharat Rozgar Yojana (ABRY) scheme and certain short remittance of EPF contribution.	February 1, 2024
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for Suspension of Drug License for the store situated at Mallathahalli (Ware-House) for 1 day due to Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	February 1, 2024
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for Suspension of Drug License for the store situated at Maruthi Nagar & Anekal Road Chandapura for 1 day & Gandhi Chowk Saundatti for 4 days respectively due to Violation of various conditions of license	February 8, 2024

issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	
The Company has informed about the receipt of order to its subsidiary company from the food and Drug Administration for Suspension of Drug License for the store situated at Palash Tower, Andheri for 12 days respectively due to Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	February 14, 2024
The Company has informed about the receipt of order to its subsidiary company from the food and Drug Administration for Suspension of Drug License for the store situated at Khopat Thane for 15 days respectively due to Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	February 15, 2024
The Company has informed about the receipt of order to its subsidiary company from the food and Drug Administration for suspension of drug license for 30 days for its store situated at Vinay Nagar, Nashik, Maharashtra due to violation of various conditions of license issued pursuant to provisions of Section 65 and Rule 65(2), 65(3), 65(6), 66(1), 66(2), 65(3)(1)(n), 65(11)(c), 65(3)(1), 65(6) of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.	February 17, 2024
The Company has informed about the receipt of order to its Subsidiary Company from the Drug & Control authority for Temporary suspension of Drug License for the store situated at Sadashiv Nagar Circle and Adarsha Nagar for a period of 3 and 1 day(s) respectively due to violation Under Section 65 (2) of Drugs and Cosmetics Act, 1940 read with Rule 65(2) of Drugs and Cosmetics Rules, 1945. The Company further informed about the Potential Revenue Loss of Rs. 2.70 Lacs due to the said order.	February 19, 2024
The Company has informed about the receipt of order to its Subsidiary Company from the Drug & Control authority for Temporary suspension of Drug License for a store situated at Uchilakere NH 66, Bangalore, Karnataka for of two days due to violation Under Section 65 (2), 65(6) ,65 (4) (3) (ii) 65 (3) (1) (h) of Drugs and Cosmetics Act, 1940 read with Rule 65(2) of Drugs and Cosmetics Rules, 1945. The Company further informed about the Potential Revenue Loss of Rs. 0.63 Lacs due to the said order.	February 20, 2024
<p>The Company has informed about as the decision of its Board as follows :</p> <ol style="list-style-type: none"> 1) Diagnostic Business: Defer the expansion plans for Diagnostics Division beyond Hyderabad, until the profitability of the pilot project is established. 2) Pharmacy Business: Expansion of Pharmacy business through internal accruals and working capital loan etc. <p>Considering the above, the Board has decided not to proceed with the fund-raising approval received from the shareholders on November 30, 2023.</p>	February 21, 2024
<p>The Company has informed about the receipt of order to its Subsidiary Company from the drug & control authority for temporary suspension of drug license for the stores mentioned below :</p> <ol style="list-style-type: none"> 1) store situated at Tarran Tallav and Motwani Road, Nashik for ten days each due to violation under Under Rule 65(6), 65(4)(4)(ii), 65(6), 65(3)(1)c, 65(3)(1) under Drugs and Cosmetics Act, and Rules, 1945. 2) store situated at Sarakki JP Nagar Metro Station, Bangalore, Karnataka for one day due to violation Under Section 65(2), 65(4) (3) 65(3)(1) (g) 65 (3) (1) (h) 65 (11) (c) of Drugs and Cosmetics Act, 1940 read with Rule 65(2) of Drugs and Cosmetics Rules, 1945. <p>The Company further informed about the Impact on financial operation due to the receipt of above order as follows :</p>	February 22, 2024

<ol style="list-style-type: none"> 1) Potential Revenue Loss of Rs. 4.25 Lacs due to suspension of drug licence of store situated at Tarran Tallav and Motwani Road, Nashik. 2) Potential Revenue Loss of Rs. 0.82 Lacs due to suspension of drug licence of store situated at Sarakki JP Nagar Metro Station, Bangalore, Karnataka. 	
<p>The Company has informed about the receipt of order to its subsidiary company from the drug & control authority for Temporary suspension of Drug License for one day a store situated at 2nd main road, Rajappa Garden Srinidhi Layout, Chunchaghatta Road, Bangalore due to violation under Section 65(2), 65(4)(3), 65(4)(4), 65(11)(c) of Drugs and Cosmetics Act, 1940 read with Rule 65(2) of Drugs and Cosmetics Rules, 1945. The Company further informed about the Potential Revenue Loss of Rs. 0.23 Lacs due to the said order.</p>	February 23, 2024
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for Temporary suspension of Drug License for nine day a store situated at D. No. 42-65, Ground Floor, Sai Nagar Colony, Near Ram Mandir, Kurnool Road, Wanaparthy, Mahabubnagar, Telangana due to violation under Section 65(3)(1), 65(3)(2), 65(4)(3)(ii), 65(9)(a) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the Potential Revenue Loss of Rs~ 1.63 Lacs due to the said order.</p>	February 24, 2024
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for Temporary suspension of Drug License for the stores as follows :</p> <ol style="list-style-type: none"> 1) for five days a store situated at L. B .Nagar, Near Metro station due to violation Under rules 65(2),65(3)(1),65(4)(3) (i),65(4)(3)(ii),65(4)(4) (i),65(9)(a) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. 2) for one day a store situated at Arikere Mico Layout & Dinnur Opp White House & Alakunte K C Nagar Exp due to violation under Section 65(2) , 65 (4) (3) (ii) 65 (3) (1) (c) 65 (3) (1) (g) , 65 (4) (3) (ii) 65(4) (4) (i) 65 (6) 65 (11) (c) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. 3) For 3 days a a store situated at Basaveshwara Nagar Mysore due to violation under Under Section 65(2) , 65 (4) (3) (ii) 65 (3) (1) (c) 65 (3) (1) (g) , 65 (4) (3) (ii) 65(4) (4) (i) 65 (6) 65 (11) (c) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. <p>The Company further informed about the potential loss due to above orders as follows :</p> <ol style="list-style-type: none"> 1) Potential Revenue Loss of Rs. 1.38 Lacs due to suspension of dug license of store situated at L. B .Nagar, Near Metro station. 2) Potential Revenue Loss of Rs.0.54 Lacs, Rs.1.01 Lacs & Rs. 0.20 lacs due to suspension of dug license of store situated at Arikere Mico Layout & Dinnur Opp White House & Alakunte K C Nagar Exp respectively. 3) Potential Revenue loss of Rs. Rs.1.39 Lacs due to suspension of drug license of store situated at Basaveshwara Nagar Mysore. 	February 26, 2024
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for one day a store situated at Krishnappa Layout Sultanpalya, Bangalore, Karnataka due to violation Under rules 65(2), 65(4)(3)(ii), 65(3)(1) (c), 65 (3)(1)(d), 65 (3)(1) (g), 65 (4)(3)(ii), 65 (4)(4)(i), 65 (3)(1), 65(6) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 0.44 lacs due to the said order.</p>	February 27, 2024

<p>The Company has informed about the receipt of order to its subsidiary company as follows :</p> <ol style="list-style-type: none"> 1) Order from the food & drug administration for Temporary suspension of Drug License for 15 days a store situated at Nr. Wardha Nagari Sahakari Bank, Deoli, Wardha & order from the Durg & Control Authority for Temporary suspension of Drug License for 7 days a store situated at Sathynarayanapuram, Tirupathi due to vliocation under Under rules 65 (2), 65(3)(1), 65(4)(3)(i), 65(4)(3)(ii),65(4)(4) (i), 65(9)(a) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945 2) Order from the Drug & Control authority for Temporary suspension of Drug License for one day a store situated at Hirekerur Haveri due to violation under Rule 65 (20) 65 (6) 65 (6) Under Drugs and Cosmetics Act, 1940 and Rules, 1945. <p>The Company further informed about the potential loss of revenue due to above orders as follows :</p> <ol style="list-style-type: none"> 1) Potential loss of revenue of Rs. 2.48 lacs & Rs. 0.49 lacs due to suspension of drug licence of stores situated at at Nr. Wardha Nagari Sahakari Bank, Deoli, Wardha & Sathynarayanapuram, Tirupathi respectively. 2) Potential loss of revenue of Rs. 0.31 lacs due to suspension of drug licence of store situated at Hirekerur Haveri. 	<p>February 29, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for 15 days a store situated at Koparkhairne Road Sector 7, Thane due to violation Under 65(2), 65(3), 65(9), 65(11) (c), 65(4)(4)(i), 65(3)(1)(h) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 9.86 lacs due to the said order</p>	<p>March 1, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for 5 days a store situated at Haridossapuram, Chennai due to violation Under Section 18(c) Rule 65(2), 65(3)(i), 65(4)(3)(i) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 0.65 lacs due to the said order</p>	<p>March 6, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License from 07.03.2024 upto 15.03.24 a store situated at Prasant Nagar, Nashik, Maharashtra due to violation Under Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 1.49 lacs due to the said order</p>	<p>March 8, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for 7 days of a store situated at Chagallu Mandal East Andra Pradesh due to violation Under Rule 65(2) and 65(4)(4) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 1.42 lacs due to the said order</p>	<p>March 12, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for 3 days of a store situated at Bhagyanagar, Karimnagar, Telangana due to violation Rule 66 (1) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 0.67lacs due to the said order</p>	<p>March 13, 2024</p>

<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for seven days of a store situated at Vasavi Nagar, Revenue ward No. 23, Tirupati, Tirupati District, Andhra Pradesh due to violation under 65(2) 65(4)(4)(i), 65(4)(3)(i) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 1.54 lacs due to the said order</p>	<p>March 19, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for five days of a store situated at D No.10-6-81/4, Shop No.4, Ground Floor, Brundavan Residency, Brindavan Colony, Lingoijiguda (V), Saroornagar (M), Ranga Reddy (D), Telangana due to violation under 65(3)(1), 65(4)(3)(i), 65(4)(3)(ii), 65(4)(4)(i), 65(9)(a) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945. The Company further informed about the potential loss of Rs. 0.28 lacs due to the said order</p>	<p>March 21, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for seven days & twenty days of a store situated at D. No. 14/14/96, near Andra Bank, Main Road, Podili, Prakasam, Andhra Pradesh District – 523240 & Index No. 10403424, House No. 104/1793/001, Ram Nagar, Ashoknagar, Satpur, Nashik – 422102 respectively due to violation under under the Drug and Cosmetic Act 1940 and Rules 1945.</p> <p>The Company further informed about the potential loss of Rs. 3.15 lacs & Rs.4.62 lacs from temporary suspension of drug licence of stores situated at D. No. 14/14/96, near Andra Bank, Main Road, Podili, Prakasam, Andhra Pradesh District – 523240 & Index No. 10403424, House No. 104/1793/001, Ram Nagar, Ashoknagar, Satpur, Nashik – 422102 respectively due to the above orders.</p>	<p>March 22, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for 7 days a store situated at D No.25-11-253, Ground Floor, in Sy.No.1006, Diesel colony, Bapujinagar, Khazipet, Hanumakonda due to violation under 65(2), 65(3)(2), 65(4) (3)(ii), 65(4) (4)(i), 65(4)(4)(ii), 65(6) of the Drugs and Cosmetics Act 1940 and Rules 1945. The Company further informed about the potential loss of Rs. 2.10 lacs due to the said order.</p>	<p>March 24, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for 8 days a store situated at S. No. 273/3 Audumber Vihar, Shreedhar Nagar, Chinchwad, Pune due to violation under Rule 65 (15)(b) ,65(3),65(4)(4)(i),65 (6),65(9) under Drugs and Cosmetics Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs. 8.17 lacs due to the said order.</p>	<p>March 27, 2024</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License of stores as follows :</p> <ol style="list-style-type: none"> 1) four days of a store situated at Nandi Hills Meerpet, due to violation under Rule 65 (15)(b) ,65(3),65(4)(4)(i),65 (6),65(9) under Drugs and Cosmetics Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs. 2.48 lacs due to the said order. 2) for one day of a store situated at Sy. No. 122/3 & 122/5, Chidri, Bidar – 580403 due to violation under Rule 65(1) under the Drug and Cosmetic Act 1940 and Rules 1945. The Company further informed about the potential loss of Rs. 0.07 lacs due to the said order 	<p>March 30, 2024</p>

<p>3) for two days of a store situated at P.No189z/5a/2c Shop No. 3, W.No. 9, Sbr Jain Complex, Near Ksrtc Bus Stand, Holagundi Road, Hoovinahadagali -583129. The Company further informed about the potential loss of Rs. 0.24 lacs due to the said order</p>	
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for five days of a store situated at NGOS Colony Hanamkonda, Telangana due to violation Under Rule 65(2), 65(4)(3)(ii), 65(9)(a) under the Drug and Cosmetic Act 1940 and Rules 1945. The Company further informed about the potential loss of Rs. 3.29 lacs due to the said order.</p>	<p>April 2, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for</p> <ol style="list-style-type: none"> 1) fifteen days of a store situated at Pheroazshah Ville Parle, Mumbai, Maharashtra due to violation Under Rule 65(3), 65(2), 65(9)(A), 65(16) & 65(11)(C) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which caused potential loss of revenue of Rs.8.62 lacs. 2) for fifteen days of a store situated at Old Nagardas Road-Andheri, Mumbai, Maharashtra due to violation under Rule 65(3)(1), 65(4)(4)(ii), 65(9)(A), 65(4)(3)(ii) & 65(16)(C) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which caused potential loss of revenue of Rs.8.37 lacs. 	<p>April 11, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for Fourteen days of a store situated at Rammandir, Dag No. 1956 & 1957, Kh. No. - 2036, JI No. - 16, Mouza - Simla, P.O & P.S - Chinsurah, Dist. - Hoogly, PIN - 712102 due to violation Under Rule 65(3)(1)(g), 65(4)(1)(f) under the Drug and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs. 11.18 lacs due to the said order.</p>	<p>April 13, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority</p> <ol style="list-style-type: none"> 1) Temporary suspension of Drug License for five days of a store situated at House No. 815/ISPD/S02, Index No. 81506441, Ishwar Paradise Apartment, Ashoka Marg, Nashik, Maharashtra 422011 due to violation under Rule 66(1) under the Drug and Cosmetic Act, 1940 and Rules, 1945 , which further resulted into the potential loss of Rs. 1.80 lacs. 2) Cancellation of Drug Sales License of its store situated at Shop No. 3 & 4 Ground Floor, O Wing, Ashapura Enclave, Plot No. 2, 3 & 4, Survey No. 326/1, Pathardi Devlali Link Road, Patharadi Phata, Nashik- 422010 due to violation under Rule 65(2), 65(3)(1), 65(2), 65(4)(1), 65(11-A) under the Drug and Cosmetic Act, 1940 and Rules, 1945. 	<p>April 15, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for three days of a store situated at Shop No. 1, Ground Floor, Site No. 617, Ward No. 53, CTS No. 8160, Malamaruti Extension, Sreenagar, Belagavi, Karnataka 590009 due to violation Under Rule 65(2), 65(9)(a), 65(6), 65(4)(3)(ii) under the Drug and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs. 0.68 lacs due to the said order.</p>	<p>April 16, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority as follows :</p> <ol style="list-style-type: none"> 1) Temporary suspension of Drug License for three days of a store situated at Shop No. 1, Ground Floor, Shaha Complex, K.C Road, Chikkodi, Belgaum, Karnataka 591201 due to violation under Rule 65(2), 65(9)(a), 65(4)(3)(i), 65(6) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs. 0.78 lacs. 	<p>April 18, 2024.</p>

<p>2) Temporary suspension of Drug License for one day of a store situated at Shop No. 10,11 & 12, CTS No. 7366 & 7367, M.M Extension, Sector No. 10, Anjaneya Nagar, Belagavi - Karnataka -590016 due to violation under Rule 65(6), 65(4)(3)(ii), 65(6), 65(11)(c) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs.0.28 lacs.</p>	
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority as follows :</p> <ol style="list-style-type: none"> 1) Temporary suspension of Drug License for forty five days of a store situated at Shop No 8&9, Silver Apartments CHS LTD., Shankar Ghanekar Marg, Prabhadevi, Dadar (West), Mumbai, Maharashtra-400028 due to violation under Rule 65(3), 65(2), 65(6), 65(4), 18(c) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs. 41.91 lacs. 2) Temporary suspension of Drug License for forty days of a store situated at Shop No. 1&2, Ground Floor, Queens Corner, CHS LTD., Plot No.395, Shitladevi Mandir Road, Mahim (West), Mumbai, Maharashtra-400016 due to violation under Rule 65(16), 62(2), 65(3), 65(4)(4)(ii), 65(6) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs.22.40 lacs. 3) Temporary suspension of Drug License for three days of a store situated at Shop No. 04, CTS No. 9362, KHB Complex, Mahantesh Nagar, Belagavi, Karnataka 590016 due to violation under Rule 65(2), 65(9)(a), 65(6), 65(4)(3)(ii), 65(6) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into potential loss of Rs.1.06 lacs. 	<p>April 23, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority as follows :</p> <ol style="list-style-type: none"> 1) Temporary suspension of Drug License for two days of a store situated at Pindi Narayana Reddy Colony Phase 2, Telangana due to violation under Rule 65(3)(1), 65(4)(3)(ii) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs. 0.37 lacs. 2) Temporary suspension of Drug License for five days of a store situated at D No. 11-23- 2374/2, Deshaipet Road, Near Filter bed, Khila Warangal (V), Khila Warangal (M), WARANGAL (D), Telangana due to violation under Rule 65(2), 65(3)(1), 65(18) under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs.12.21 lacs. 	<p>April 26, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for three days of a store situated at Shop No. 1, Ground Floor, Site No. 617, Ward No. 53, CTS No. 8160, Malamaruti Extension, Sreenagar, Belagavi, Karnataka 590009 due to violation Under Rule 65(2), 65(9)(a), 65(6), 65(4)(3)(ii) under the Drug and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs. 0.68 lacs due to the said order.</p>	<p>April 30, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for one day of each store situated at Railway Station Road, Bijapur and Mahalaxmi Complex, M.G Road, Bijapur Karnataka, respectively due to violation Under Rule 65(6), 65(6), 65(3)(1), 65(4)(3)(i), 65(4)(3)(i)(a), 65(3)(1)(g), 65(11)(c) under the Drug and Cosmetic Act, 1940 and Rules, 1945. The Company further informed</p>	<p>May 2, 2024.</p>

about the potential loss of Rs. 0.23 lacs & 0.64 lacs respectively due to the said order.	
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for three days of store situated at Shop No. 2 G.F, M.B Shalavadi Complex, Gadag Karnataka-582103 due to violation Under Rule 65(2), 65(9)(a), 65(6), 65(4)(4)(ii), 65(3)(1), 65(3)(1)(h) under the Drug and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs.2.43 lacs respectively due to the said order.	May 4, 2024.
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority as follows : <ol style="list-style-type: none"> 1) Temporary suspension of Drug License for seven days of store situated at D. No. 44/4, Prakash Nagar, Kurnool District - Andhra Pradesh due to violation under Rule 65(2), 65(4)(3)(ii), 65(3)(1)(h) & 65(4)(1) under the Drugs and Cosmetic Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs. 3.74 lacs. 2) Temporary suspension of Drug License for seven days of store situated at Ward No. 31, H Cross Road, C.B Pura Road, Kolar, Karnataka - 563101 due to violation under Rule 65 under the Drug and Cosmetic Act, 1940 and Rules, 194, which further resulted into the potential loss of Rs.1.01 lacs. 3) Temporary suspension of Drug License for seven days of store situated at P. No. 430/2, AR No.15/58, Ground Floor, Ward No. 15, Near KEB Office, Opposite UCO Bank MB Road, Kolar, Karnataka – 563101 due to violation under Rule 65 under the Drug and Cosmetic Act, 1940 and Rules, 1945, which further resulted into potential loss of Rs.0.73 lacs. 	May 5, 2024.
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for one day of store situated at Madhugiri, Karnataka – 572132 due to violation Under Rule 65 of the Drugs and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs.0.31 lacs due to the said order.	May 8, 2024.
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for three days of store situated at Armoor, Nizamabad Telangana due to violation Under Rule 65(2), 65(4)(4)(i) of the Drugs and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs.0.40 lacs due to the said order.	May 9, 2024.
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for four days of store situated at SBH Colony Hanamkonda, Warangal, Telangana due to violation Under Rule 65(3)(2), 65(4)(3)(ii), 65(4)(4)(i), 65(4)(4)(ii) of the Drugs and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs.2.08 lacs due to the said order.	May 10, 2024.
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for three days of store situated at D. No. 15/506, Venkatapuram, Nellore, SPSR Nellore Dist, Andhra Pradesh due to violation Under Rule 65(4)(3) and 65(4)(4) of the Drugs and Cosmetic Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs.0.39 lacs due to the said order.	May 11, 2024.
The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority as follows :	May 15, 2024.

<ol style="list-style-type: none"> 1) Temporary suspension of Drug License for seven days of store situated at Biragipatteda, Tirupathi, Andra Pradesh due to violation under Rule 65(2) Drugs and Cosmetics Rules 1945, and Rules 65(4)(4)(i) and 65(4)(3)(i) of Drugs and Cosmetics rules 1945, which further resulted into the potential loss of Rs. 2.80 lacs. 2) Temporary suspension of Drug License for fourteen days of store situated at Chawk Bazar, Chinsurah, Hooghly, West Bengal due to violation Rule-66(1) of Part VI of the Drugs and Cosmetics Act 1940 and Rules 1945, which further resulted into the potential loss of Rs.5.01 lacs. 	
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for two days of a store situated at Rudrur, Telangana due to violation Under Rule 65(3)(1), 65(4)(3)(ii), 65(4)(4)(i) under Drugs and Cosmetics Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs.0.44 lacs due to the said order.</p>	<p>May 18, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority for temporary suspension of Drug License for five days of a store situated at Sai Nagar Rd Chaitanyapuri Kothapet Exp, Telangana due to violation Under Rule 65(2), 65(3)(1), 65(4)(3)(i), 65(4)(3)(ii), 65(4)(4)(i), 65(18) under Drugs and Cosmetics Act, 1940 and Rules, 1945. The Company further informed about the potential loss of Rs.0.41 lacs due to the said order.</p>	<p>May 21, 2024.</p>
<p>The Company has informed about the receipt of order to its subsidiary company from the Drug & Control Authority as follows :</p> <ol style="list-style-type: none"> 1) Temporary suspension of Drug License for one day of a store situated at Lalithadripura Exp, Karnataka due to violation under Rule 65(2), 65(4)(4)(ii) & 65(6), 65(4)(3) (i) & 65(6), 65(4)(4)(ii) 65(4)(3)(i) & 65(6) under Drugs and Cosmetics Act, 1940 and Rules, 1945, which further resulted into the potential loss of Rs. 0.24 lacs. 2) Temporary suspension of Drug License for two days of a warehouse situated at FMCG Ware House, Karnataka due to violation under Rule FORM 20,21&20B,20G 64(1) , 65 (4) (3) 65 (4) (4) & 65 (6) ,65 (5) (1) , 65 (17) , 64 (1) ,65 (17) ,65 (17) 64 (1) ,64 (1) 65 (17) under Drugs and Cosmetics Act, 1940 and Rules, 1945. 3) Temporary suspension of Drug License for two days of a warehouse situated at Optival Ground Floor Ware House, Karnataka due to violation under Rule 65(17) 64 , 65 (4) (3) & 65 (5) (2) ,65 (4) (4) (1) , 65 (5) (3) 65 (6) ,65 (17) , 65(6) , 65(4)(3) 65(5) (1) 65(4) (4) ,65 (5) (3) 65 (6) under Drugs and Cosmetics Act, 1940 and Rules, 1945. <p>Temporary suspension of Drug License for one day of a warehouse situated at Optival Ware House, Karnataka due to violation under Rule 20B & 21B, 65(17) , 65, 65(5)(2) 65(6), 65(17) 64, 65 (6) under Drugs and Cosmetics Act, 1940 and Rules, 1945</p>	<p>May 27, 2024.</p>

Source- Stock Exchange Filings

All the above information has been updated till May 30, 2024 unless indicated otherwise